텔콘RF제약

200230KOSDAQ의약품 제조업

66.7 / 100

Reference Date: 2026-07-24

Financial Score24.0 / 40

News Sentiment16.7 / 25

Momentum12.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 483.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Telcon RF Pharmaceuticals primarily manufactures connectors and cable assemblies for wireless communication equipment, expanding into optical solutions and 5G FTTA (Fiber-To-The-Antenna) technology to strengthen its global market position. In the pharmaceutical and biotech sector, the company produces various dosage forms using KGMP-certified facilities and invests in new drug development.

Number of Employees

133people

Average Salary

55.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.14Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE

-11.91Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

1.46Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲9.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲505.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.4% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 3Neutral 3Negative 0Average Sentiment Score 66.7

Positive
실소유주 50억원 투입... 텔콘 3형제, 상폐 위기 해소하고 순환출자...
텔콘RF제약은 실소유주 투자와 순환출자를 통해 시가총액을 확대하고 상폐 위기를 극복하는 전략을 취하고 있어 긍정적인 신호를 받고 있다.
Neutral
텔콘RF제약, 50억 규모 제3자배정 유상증자 결정
텔콘RF제약의 50억원 규모 제3자배정 유상증자 결정으로 자금 조달 계획이 발표되었으나, 직접적인 시장 영향은 제한적.
Neutral
텔콘RF제약, 50억원 유상증자…에버코어인베스트먼트홀딩스에 제3자배....
텔콘RF제약의 유상증자 결정으로 자금 조달 계획이 공시되었으나, 직접적인 시장 영향은 제한적입니다.

Detailed Momentum

52-week position5.0Point

52w mid range (50%)

Current 2,100Won52-week high 3,80052-week low 360

1-month return6.0Point

1m +483.33% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

14 totalPositive 2Neutral 12Negative 0

Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-07-16
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral기타시장안내(최대주주의의무보유관련) (최대주주의 의무보유 이행 관련)2026-07-15